OCUL Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Ocular Therapeutix Inc (OCUL) is a good buy for a beginner investor with a long-term strategy and $50,000-$100,000 available for investment. The stock has strong analyst support with multiple buy ratings and increased price targets, positive sentiment around its Axpaxli drug development, and hedge fund buying activity. While there are some concerns about insider selling and recent financial performance, the long-term growth potential in the wet AMD market outweighs these negatives.
The MACD is positive at 0.391, indicating bullish momentum. RSI is neutral at 58.989, suggesting no overbought or oversold conditions. Moving averages are converging, and the stock is trading above its pivot level of 9.371, with resistance levels at 11.096 and 12.161. These indicators suggest a moderately bullish trend.
Multiple analysts have raised price targets significantly, with the highest target at $34, citing positive Phase 3 SOL-1 trial data and strong potential for Axpaxli in the wet AMD market.
Hedge funds have increased their buying activity by 2312.47% over the last quarter.
The stock is up 0.97% in pre-market trading, reflecting positive sentiment.
Insiders have increased selling activity by 186.05% over the last month.
The company's Q4 financials show a revenue decline of -22.43% YoY and a gross margin drop of -5.20% YoY, indicating operational challenges.
In Q4 2025, revenue dropped by -22.43% YoY to $13.25M, while net income improved by 33.62% YoY to -$64.65M. EPS remained flat at -0.29. Gross margin declined by -5.20% YoY to 87.97%. While revenue and gross margin are concerning, the improvement in net income suggests some operational efficiency gains.
Analysts are overwhelmingly positive on OCUL, with multiple buy ratings and price targets raised to as high as $34. Analysts highlight Axpaxli's potential as a major improvement in the wet AMD market, supported by positive Phase 3 trial data and clean safety and tolerability profiles.
